Created in 1993, the act concerns
the manufacture of generic drugs.
Not exact matches
These risks and uncertainties include, among others: the unfavorable outcome
of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any
of our products or products using our proprietary technologies, which may lead to competition from
generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components
of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence
of efficacy and adequacy
of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results
of our clinical development activities may not be positive, or predictive
of real - world results or
of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to
manufacture, be precluded from commercialization by the proprietary rights
of third parties, or have unintended side effects, adverse reactions or incidents
of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
After graduating from the University
of Calcutta in 1982, Dilip Shanghvi started working at his father's wholesale
generic -
drugs business, where he saw an opportunity to
manufacture Lithosun, a
drug that treated manic - depressive disorders and was unavailable in much
of eastern India.
The research behind a new
drug is protected for a fixed number
of years, after which competing firms can begin
manufacturing generic forms.
«We are calling for the
generic manufacture and widespread availability
of the
drug flucytosine, and plan large - scale programmes
of implementation with partner countries and international agencies that could result in the mortality from this dreaded infection being halved.
Varying strengths
of risperidone tablets,
manufactured by TEVA Pharmaceuticals USA, have been approved, although the labeling
of the
generic risperidone might differ from that
of Risperdal because some uses
of the
drug are protected by patents and exclusivity, the agency said.
(That's different from
manufacturing a small - molecule
generic, which will have the exact chemical structure
of the brand - name
drug.)
This could be great too as Jean - Coutu owns a
generic drug brand and
manufacture but... I think that in Ontario or another province, they recently forbid pharmacists to also be owners
of drug manufactures... So time will tell but I expect a lot
of volatility with that title for a while.
Like many
drugs, there are a number
of names by which Clomipramine can go by, including Anafanil (made by Novartis,) Clomicalm (
manufactured by Novartis) or the
generic Clomipramine Hydrochloride.
Ratiopharm Inc. v. Canada (Attorney General) 2014 FC 502 Constitutional Law — Statutes — Trade Regulation Summary: Ratiopharm Inc. sold
generic drugs in Canada, including ratio - salbutamol HFA («ratio HFA»), the
generic equivalent
of Ventolin HFA, a product
manufactured by GlaxoSmithKline Inc. (GSK).